Endocrine Abstracts (2006) 11 P46

The effect of once-weekly Risedronate on biochemical markers of bone turnover after three month of treatment

D Paun, D Grigorie, A Ghemigian, F Cofaru & C Dumitrache


Institute of Endocrinology, Bucharest, Romaina.


The nitrogen-containing bisphosphonate Risedronate have been shown to reduce the risk of both spine and nonspine fractures by reducing bone turnover, increasing bone mass and improving bone strength.

Objective: To study the effects of once-weekly Risedronate on bone turnover markers in osteoporotic patients after three month of treatment.

Patients and methods: Study group included 50 osteoporotic patients (3 males and 47 females), mean age (+/− DS) of 62.06+/−9.61 years, without previous medication for osteoporosis. 19 patients (38%) had previous low-impact fracture, 4 patients (8%) had family history of osteoporosis and 6 patients (12%) were smokers. Dual X-ray apsorbtiometry of the lumbar spine was performed baseline.

We measured serum levels of osteocalcin as a marker of bone formation and beta crosslaps as a marker of bone resorbtion by immunoassay at the time of diagnosis and after three month of treatment.

Once-weekly Risedronate was administered in all patients; they were also received calcium /vitamin D substitution.

Results: The osteocalcin levels were found to be 38.8+/−2.4 ng/ml at the baseline and 16.6+/−1.6 ng/ml after three month of treatment. The beta crosslaps levels were 0.741+/−0.09 ng/ml at the baseline and 0.138+/−0.04 ng/ml after three month of treatment. It was shown that Risedronate significanthtly decreases osteocalcin levels and beta cross laps after three month of treatment. The medication was well-tolerated with no upper gastrointestinal adverse experiences.

Conclusion: In this study, the use of once-weekly Risedronate was associated with the significant reduction in both formation and resorbtion biochemical markers of bone turnover after three month of treatment.

Article tools

My recent searches

No recent searches.